Sigilon Therapeutics Inc (SGTX) USD0.001
Sigilon Therapeutics, Inc. is a biopharmaceutical company with a platform of biomedical technologies and cell therapies created to avoid host detection and foreign body responses with a goal of providing functional cures to patients with chronic diseases. The Company has developed its Shielded Living Therapeutics (SLTx) platform, which combines cell engineering in biocompatible materials and enables its product candidates to produce a range of therapeutic molecules, which may be missing or deficient, such as proteins, including therapeutic proteins and antibodies, and hormones. The Company is designing its product candidates to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression. Its lead product candidate, SIG-001, is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A by continuously secreting human Factor VIII (FVIII).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.